Composition for preventing or treating fatty liver or metabolic syndrome containing Lactococcus chungangensis

Fatty liver and metabolic syndrome improvement material based on the novel probiotic Lactococcus chungangensis derived from wastewater

This technology involves pharmaceutical and food compositions for the prevention and treatment of fatty liver or metabolic syndrome, containing at least one of the following as an active ingredient: Lactococcus chungangensis strain, its culture, or a product fermented with this strain. The food composition can also be implemented in the form of fermented foods or cheese.

Metabolic syndrome, characterized by obesity-related insulin resistance, involves a combination of hyperglycemia, hypertension, and dyslipidemia, which increases the risk of diabetes, atherosclerosis, and cardiovascular disease, and can lead to non-alcoholic fatty liver disease. However, exercise regimens are difficult to maintain, drug therapies often cause side effects like abdominal pain, steatorrhea, and vomiting, and surgical interventions like liposuction or gastric bypass carry safety risks, leaving a shortage of effective treatments for metabolic syndrome.

This technology utilizes the strain with accession number KCTC 12684BP in the form of live bacteria, dead bacteria, dried bacteria, or culture supernatant. Fermented products made by using this strain as a starter for dairy or natural products also serve as active ingredients. It targets obesity, dyslipidemia, hyperlipidemia, diabetes, and insulin resistance syndrome by suppressing weight gain, blood glucose, and cholesterol levels, while lowering liver damage markers. Applicable to functional fermented dairy products like cream cheese, probiotics for fatty liver management, and metabolic syndrome treatment supplements, it offers a food-based solution to manage obesity and fatty liver through daily consumption of cheese and fermented foods.

‍

‍

Key Features:

• Pharmaceutical composition for preventing or treating fatty liver or metabolic syndrome, comprising at least one of Lactococcus chungangensis strain, its culture, or its fermented product as an active ingredient
• Pharmaceutical composition for treating fatty liver or metabolic syndrome, comprising the Lactococcus chungangensis strain with accession number KCTC 12684BP as an active ingredient
• Composition for preventing or treating metabolic syndrome selected from obesity, dyslipidemia, hyperlipidemia, diabetes, and insulin resistance syndrome
• Food composition for preventing or improving fatty liver or metabolic syndrome, comprising the strain, culture, or fermented product as an active ingredient and formulated as a fermented food or cheese

‍